The Case for a COVID-19 EBITDA Adjustment
In this timely webinar, John Wagner, managing director of 1st West M&A, makes the case for how to treat reduced (or outright lost) EBITDA caused by the COVID-19 pandemic when negotiating a company’s value.
The pandemic is temporary, and should not reduce a company’s long-term valuation. John explains how companies who are selling or recapitalizing their business should demand a “COVID-19 EBITDA adjustment” when negotiating their company’s value.
Some points of discussion:
- EBITDA lost to the pandemic should not be fully averaged into your annual EBITDA
- COVID-19 will negatively affect you
- Stick to Your Guns…